Phentolamine mesylate in postmenopausal women with female sexual arousal disorder: A psychophysiological study
Por:
Rubio-Aurioles E., Lopez M., Lipezker M., Lara C., Ramírez A., Rampazzo C., Hurtado De Mendoza M.T., Lowrey F., Loehr L.A., Lammers P.
Publicada:
1 ene 2002
Resumen:
The objective of this study was to assess the potential of phentolamine as a treatment of postmenopausal women with female arousal disorder (FSAD). Vaginal photoplethismography and a subjective questionnaire were used. Forty one women were enrolled and four treatments were tested: vaginal solutions 5 mg and 40 mg and an oral tablet each of 40 mg of phentolamine and placebo. Physiological readings were significantly different from placebo in the women using hormone replacement therapy (HRT) with 40 mg of phentolamine in vaginal solution (p = 0.0186). Subjective reports also were significantly different from placebo with the vaginal solution 40 mg and the oral tablet of 40 mg of phentolamine among hormone replacement users. No significant differences were found among women not receiving HRT. Results indicate that phentolamine may show promise as treatment for FSAD in estrongenized postmenopausal women.
Filiaciones:
Rubio-Aurioles E.:
Asociación Mexicana para la Salud Sexual, Mexico City, Mexico
Lopez M.:
Hospital Español de México, Mexico City, Mexico
Lipezker M.:
ECA México, Mexico City, Mexico
Lara C.:
ECA México, Mexico City, Mexico
Ramírez A.:
ECA México, Mexico City, Mexico
Rampazzo C.:
Asociación Mexicana para la Salud Sexual, Mexico City, Mexico
Hurtado De Mendoza M.T.:
Asociación Mexicana para la Salud Sexual, Mexico City, Mexico
Lowrey F.:
Zonagen Inc. USA, The Woodlands, TX, United States
Loehr L.A.:
Zonagen Inc. USA, The Woodlands, TX, United States
Lammers P.:
Zonagen Inc. USA, The Woodlands, TX, United States
|